Navigation Links
Sutro Biopharma Secures $36.5 Million in Series C Financing
Date:11/17/2010

SAN FRANCISCO, Nov. 17, 2010 /PRNewswire/ -- Sutro Biopharma today announced that the company has secured $36.5 million in Series C financing. This financing will support the company's ongoing development of novel biotherapeutics with superior pharmaceutical properties and advance the company's biochemical protein synthesis platform to meet current Good Manufacturing Practice (cGMP) standards.

Led by Skyline Ventures, the financing round, which consists of two tranches, includes participation from new investors, Lilly Ventures and Amgen Ventures, and existing investors, SV Life Sciences and Alta Partners. The first tranche of $20 million closed on Nov. 5.

"Skyline Ventures is delighted to lead this round of financing as we believe that Sutro's programs, technology and capabilities have significant market potential in many different applications," said Leon Chen, Ph.D., Partner at Skyline Ventures. "We believe that the novel biotherapeutics developed with Sutro's technology will effectively address the tremendous unmet needs that still remain in a wide variety of diseases."

In conjunction with the financing, Dr. Chen and Armen Shanafelt, Ph.D., Venture Partner at Lilly Ventures, have joined Sutro's board of directors.

William Newell, Chief Executive Officer of Sutro Biopharma, said, "Securing this major investment in the current economic environment demonstrates our investors' enthusiasm and belief in the transformative potential of our programs and our biochemical protein synthesis technology. The financing provides us with sufficient capital to drive our own programs to the clinic and to support our collaborative relationships, which focus on therapeutic proteins that have been inaccessible until now."

To date, the company has raised a total of $59.5 million in financing.

About Sutro BiopharmaSutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that hav
'/>"/>

SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ), ... small molecule drugs for the treatment of cancer and ... host a conference call and live audio webcast on ... the company,s second quarter fiscal 2011 financial and operational ...
... Health today announced that its board of directors has approved a ... to shareholders of record on April 1. This marks the 106th ... Cardinal Health Headquartered in Dublin, Ohio, Cardinal ... health care services company that improves the cost-effectiveness of ...
Cached Medicine Technology:Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011 2Cardinal Health Declares Regular Quarterly Dividend 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CITY, Iowa, May 6 Quatro Composites, ... composite products, has been,awarded ISO 9001:2000 and ... of its facilities, located in Orange City, ... of the AS9100 quality management,system., "Receiving ...
... 20% Year-Over-Year ... Cost Reduction Efforts Show ... Ends the Quarter with $10.5 Million in Cash, MONROVIA, Calif., May ... and marketer of,minimally invasive ophthalmic products, today reported good progress during,its first ...
... finds short-term dysfunction while awaiting operation rarely turns ... -- Few patients who have short-term kidney dysfunction ... problems once they have their transplant, says a ... have kidney dysfunction while awaiting liver transplantation, which ...
... Demonstrate to Protect Their Voice & Vote at,SEIU Hearing, ... the direction of the Service Employees International Union (SEIU),intensified ... was held to,determine the fate of more than 60,000 ... West (UHW). UHW represents 150,000,caregivers in hospitals, clinics, nursing ...
... Management: Making a ... Difference Today and Tomorrow, HARRISBURG, Pa., ... Officer, will deliver the clinical keynote,address on Wednesday afternoon, May ... World of Care Management. Dr. Petrulis will,present Care Management: Making ...
... aid couples trying to conceive , , TUESDAY, May 6 ... the lubricant they use wisely because some lubricants can ... commercial lubricants are toxic to sperm, and couples who ... they want," said study author Dr. William H. Kutteh, ...
Cached Medicine News:Health News:Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification 2Health News:STAAR Surgical Reports Solid First Quarter Progress 2Health News:STAAR Surgical Reports Solid First Quarter Progress 3Health News:STAAR Surgical Reports Solid First Quarter Progress 4Health News:STAAR Surgical Reports Solid First Quarter Progress 5Health News:STAAR Surgical Reports Solid First Quarter Progress 6Health News:STAAR Surgical Reports Solid First Quarter Progress 7Health News:STAAR Surgical Reports Solid First Quarter Progress 8Health News:STAAR Surgical Reports Solid First Quarter Progress 9Health News:STAAR Surgical Reports Solid First Quarter Progress 10Health News:STAAR Surgical Reports Solid First Quarter Progress 11Health News:STAAR Surgical Reports Solid First Quarter Progress 12Health News:Kidney Trouble Short-Lived in Most Liver Transplant Patients 2Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 3
... growth factor I (IGF-I or somatomedin C) is ... liver. It acts as a potent mitogen of ... specific cell-surface receptors. In the circulation, IGF-I is ... regulate the actions of IGF-I by modulating the ...
... potent naturally occurring androgen produced from ... 5a-reductase [1]. The concentrations of ... tissues, including genital skin and hair ... apparent association with the nuclear membrane. ...
Urovac bladder evacuator with adaptor...
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Medicine Products: